Globus Medical Reports Q3 Results, Cuts 2026 Revenue Guidance
Globus Medical reported Q3 net sales of $763.7 million, down 0.7% year over year, and GAAP diluted EPS of $1.04, up 18.2%. It increased its share repurchase program by $500 million and lowered 2026 revenue guidance to $3.09 billion from $3.18 billion–$3.22 billion, while reaffirming non-GAAP diluted EPS guidance of $4.95–$5.05.
Globus Medical, Inc. reported worldwide net sales of $763.7 million for the third quarter ended September 30, 2026, representing a 0.7% decrease compared to the prior year. The company reported GAAP net income of $141.2 million, with GAAP diluted EPS of $1.04, an 18.2% increase year-over-year. Non-GAAP diluted EPS was $1.23, up 4.4% from the same period in 2025.
Alongside the earnings release, the company announced a $500 million increase to its share repurchase program. Additionally, the company updated its full-year 2026 revenue guidance to $3.09 billion, down from its previous range of $3.18 billion to $3.22 billion, while reaffirming its non-GAAP fully diluted EPS guidance of $4.95 to $5.05.